chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19; Coughing; Felling cold; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Coughing), FEELING COLD (Felling cold) and COVID-19 (COVID-19) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038A21A and 024M20A) for COVID-19 vaccination.     Concurrent medical conditions included Cholesterol. Concomitant products included ATORVASTATIN (LIPTOR [ATORVASTATIN]) for Cholesterol.   On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Dec-2021, the patient experienced COUGH (Coughing) and FEELING COLD (Felling cold). On 22-Dec-2021, the patient experienced COVID-19 (COVID-19). On 26-Dec-2021, COUGH (Coughing) and FEELING COLD (Felling cold) had resolved. At the time of the report, COVID-19 (COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Dec-2021, SARS-CoV-2 test: positive (Positive) positive COVID rapid antigen COVID test.         No medical history was provided. No treatment medications were reported. Company comment This case concerns a male patient of an unknown age, with no reported relevant medical history, who experienced the unexpected non-serious event of COVID-19 (AESI). The events occurred approximately 11 days after the administration of the third dose of mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a male patient of an unknown age, with no reported relevant medical history, who experienced the unexpected non-serious event of COVID-19 (AESI). The events occurred approximately 11 days after the administration of the third dose of mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Information has been received from a consumer reporting that she knew some friends who had their children vaccinated with a dose of MMR II and later developed autism. Upon internal review, autism was determined to be an other important medical event. This is one of several reports from the same source. Attempts to verify the existence of identifiable patients have been unsuccessful.
Breakthrough case admission after 2 vaccines  Moderna 1/21/21 lot# 032H20A;  Moderna 2/18/21 lot# 010M20A
slow onset of severe arthralgia/ joint pains and memory problems, and fogginess, shortness of breath
no symptoms other than cough. Home Covid test done after wife tested positive on a home Covid test as well as 10 out of 13 people in our group on a cruise. All persons in our party tested negative prior to the cruise. Dr Office was called and script for Paxlovid was sent out.
Vomiting within 15 minutes Fever 1 hr post vaccination Continued vomiting
Patient came with parent for her first Covid-19 Vaccine. Patient filled out paperwork. The patient's mom stated that she wanted her daughter to get Moderna. I as the vaccinator went over side effects with patient. Patient understood and was given her vaccine. Patient states that she was feeling fine and left after her 15 minutes. The patient guardian has been made aware. Guardian wanted to speak with a Provider for more in depth information. Providers have been made aware.
Ataxia (truncal and gait) which developed several hours after receiving MMR vaccine on 12-4-08. 12/19/08-records received for 12/7/08-consultation for C/O tremulous shaking both arms and subsequently gait was noted to be unsteady on 12/4/08. Neuro exam shows bilateral and intentions tremor bordering on dysmetria on left, mild truncal ataxia and moderate gait ataxia. Romberg's sign negative. Plantar responses are bilaterally downgoing. Signs of cerebellitis or acute cerebellar ataxis. 2/13/09-records received for DOS 12/5-12/12/08,DC DX:Unsteady gait, porbably cerebellitis. Presented with inability to stand, shaking of both arms and unsteady ataxic leg gait. PE:dysmetria, ataxia and diadochokinesia.
Bloop pressure increased exponentially.  DIA usually in ?90s, after shot it stays in the 100, with or without medication.
Raise red petechiae noted on abdomen trunk. Also red rash welt are over navel area.
Information has been received from a physician concerning a 24 year old female patient with no known drug allergies or pertinent medical history who on 12-DEC-2008 was vaccinated with the first dose of GARDASIL (Lot number 661764/0650X). Concomitant therapy included birth control pills. The patient developed SBT (Supra Ventricular Tachycardia) and she was hospitalized. The patient could not remember the exact date of her hospital confinement when she reported the event to the physician she thought it to be two weeks after the vaccination. The patient told her physician she underwent an electrocardiogram (EKG), echocardiogram (ECHO) and exam with no results provided to the reporting physician. No surgery was performed. On an unspecified date the patient was discharged from cardiologist's care. The patient will not receive further doses of GARDASIL as the patient believed the event was caused by the vaccine. The physician reported that there was no association between SVT and GARDASIL. At the time of the report the patient had recovered. "Supra Ventricular Tachycardia" was considered by the physician to be life-threatening. No further information is available.
This spontaneous report was received from a male patient of unknown age. On 12-Sep-2013 the patient was vaccinated with ZOSTAVAX (dose, lot # and route of administration were not reported. Other suspect therapies included PNEUMOVAX 23 (dose, lot #, route of administration and indication were not reported). On 12-SEP-2013, 5 hours later, the patient experienced double vision. On13-SEP-2013 (the next day) the patient experienced issues with his equilibrium and balance. On an unknown date the patient experienced heightened anxiety and frequent headaches. The outcome of all of the events mentioned above was reported as not recovered/not resolved. Additional information has been requested.
Dizziness, tunnel vision, weakness, light headedness, near loss of consciousness about 1.5 hours after receiving vaccine dose. Lasted about 15 minutes and resolved with lying down.
4:14 Pm Pt start coughing  went outside observation door  to get Fresh  air. Bring her start itch throat. Pt skin Turn red face & arm . Provider take the Pt lung clear vital
He had the vaccine on the morning of Friday,  April 24.  That afternoon felt very tired.  Felt a little better the following day but still complaining of feeling tired.  But on the second day following the vaccine, Sunday April, the 26th, upon waking up, he looked and felt exhausted.  His eyes were really droopy.  Later into the afternoon and into the next day, April 27th, he was extremely fatigued with body aches and unusual behavior.  Very irritable and depressed. He has never displayed irritability and depression ever. He slept for 16 hours  each day the 26th, the 27th and the 28th.   Appeared a little better yesterday.  Did not exhibit as much anxiety, but still complaining of being extremely tired.  This is very unusual for him since he is used to competitive swimming and had not displayed this much fatigue even the month prior from being in quarantine from this Pandemic.
Hives started appearing days later and have not eaten anything different than the week before and have not changed shampoo, body wash, deodorant, etc or taken any medication
inflammation; he experienced numbness and tingling from the groin to the glues after the first dose of the vaccine.; he experienced numbness and tingling from the groin to the glues after the first dose of the vaccine.; muscle weakness, aching; muscle weakness, aching; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old male patient received his first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: PAA156507), via an unspecified route of administration in the left arm on 01Feb2021 at (at the age of 24-years-old) as a dose 1, single dose for COVID-19 immunisation. Medical history reported as none. The patient's concomitant medications were not reported. On 01Feb2021, the patient experienced the typical vaccine symptoms, muscle weakness and aching. On 02Feb2021, the patient fully recovered from muscle weakness and aching and on same day the patient experienced numbness and tingly-ness around the groin region, expanding to his inner thigh, along his leg, as well as glutes and he went to the doctor, the patient took Ibuprofen to take down the inflammation, and they were tried to pinpoint. The patient noticed tingliness, only on the left side where the vaccine was administered, in that arm. It had been significantly reduced, he still had some, not as intense as it was last week. Still had relative sensation, like a tingling like when foot falls asleep, not a complete loss of sensation, more that sort of tingling feeling. The patient had appointment for second dose on 23Feb2021. The clinical outcome of the events muscle weakness and aching was recovered for inflammation was unknown while recovering for rest events.  Follow-up attempts completed. No further information expected.
little headache; muscle aches; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (little headache) and MYALGIA (muscle aches) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011120A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2021, the patient experienced HEADACHE (little headache) and MYALGIA (muscle aches). At the time of the report, HEADACHE (little headache) and MYALGIA (muscle aches) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by reporter. The patient was prescribed some medications for two weeks for his blood pressure   This case was linked to MOD-2021-353242, MOD-2021-353246.
Patient received vaccine on 12-2-21 on 12-3-21 she woke up  at 7:05 am went to the bathroom and "passed out" fell to the  ground/into shower. Eyes open but not aware of what was going on. Sweaty. Called 911 vitals were stable. They said she may have been dehydrated BP was lower on  standing. Fever on 12/2/21- 101. Soreness at site of vaccine.
Uncontrollable Crying; Depression; Aggression and Physical Outbursts; Fever 105; Lasted for 2 weeks.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Physician) from product quality group. The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 29Nov2022 as dose 5 (booster), single (Lot number: GH9703) at the age of 68 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 19Dec2020 as dose 1, single (Lot number: EJ1685), in left arm, on 09Jan2021 as dose 2, single (Lot number: EL1283), in left arm, on 24Sep2021 as dose 3 (booster), single (Lot number: FF2587), in left arm and on 10Apr2022 as dose 4 (booster), single (Lot number: FM0698), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "Elevated cholesterol" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL, start date: 02Mar2020; DILTIAZEM, start date: 15Oct2021. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Mar2023, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (18Mar2023) Negative; (20Mar2023) Negative; (21Mar2023) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.
I had really bad vision and dizziness. I received new glasses and contact lenses. I'm still currently getting seen by doctors to evaluate my health impact. I was not able to drive for 5 months.
I started developing a psoriasis-like rash below my lip and spreading down to my chin. I first saw bumps 2 days after my vaccine on April 1. Thinking it was acne, I began treating it with salicylic acid. That did not help and the rash continue to grow and develop bumps like whiteheads. The spreading and discomfort of the rash prompted me to visit my local urgent care. The doctor was unable to say exactly what caused the rash. Then, I began reading about possible vaccine side effects and I saw a picture of a rash that looks just like the rash below my lip. In this article - the bottom picture looks like the rash I have.
Crohn's disease; other things; Initial information received on 28-Jun-2019 regarding an unsolicited valid serious case received from a nurse.  This case involves a male patient of unknown age who experienced crohn's disease and other things, while he received vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA].  The patient's past medical history, medical treatment(s), concomitant therapy, vaccination(s) and family history were not provided.   In 2010, the patient received a first dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE lot number not reported via unknown route and was going to get second vaccination.  On an unknown date, The patient developed a serious crohn's disease and non serious other things (unevaluable event) following the administration of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE. This event (crohn's disease) was assessed as medically significant.  Nurse asked about any concerns with administering Menactra to a patient receiving Remicade and methotrexate. Nurse stated that she did not have the patient's chart available, so she did not know whether the patient already had been diagnosed with Crohn's in 2010 and already was receiving Remicade and methotrexate, prior to his first Menactra immunization, or whether the patient was diagnosed with Crohn's and began treatment after having received the Menactra vaccine in 2010.  No lab test was reported.   Final diagnosis was other things and crohn's disease.   The patient was treated with INFLIXIMAB (REMICADE) for Crohn's disease and METHOTREXATE (METHOTREXATE) for Crohn's disease.  The event outcome was not reported.  Information on the batch number was requested; Sender's Comments: Patient presented with Crohn's disease after vaccination. Time to onset is unknown. Patient was treated with INFLIXIMAB (REMICADE) for and METHOTREXATE (METHOTREXATE) for Crohn's disease. Further information including patient's medical history, concomitant medications, laboratory investigations excluding other etiology would be needed to fully assess this case. Based on available information the role of vaccine cannot be assessed.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On an unknown date between 07-MAY-2018 and 10-JUL-2018, the patient was vaccinated with an improperly stored dose of VAQTA, lot # N026997, expiration date 10-NOV-2018; and ROTATEQ, lot # R002060, expiration date 05-JUN-2019 (dose and route of administration were not reported). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 47 to 77 degrees (also reported as "max 55 degrees") Fahrenheit for 30 minutes and above 32 up to 35 degrees Fahrenheit for 16 hours (also reported as "brief intervals of being too cold lasting for 30 minutes each, ranging from 34 to 35.6 degrees Fahrenheit"). Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1807USA009780: US-009507513-1808USA006765: US-009507513-1808USA006766: US-009507513-1808USA006767: US-009507513-1808USA006768: US-009507513-1808USA006769: US-009507513-1808USA006770: US-009507513-1808USA006771: US-009507513-1808USA006772: US-009507513-1808USA006773: US-009507513-1808USA006774: US-009507513-1808USA006775: US-009507513-1808USA006777: US-009507513-1808USA006778.
one dose of Janssen COVID-19 vaccination was given to an individual under the age of 18.
Discharge Provider: MD Primary Care Provider: MD Admission Date: 5/10/2023 Discharge Date:  05/12/2023 DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Hypoxemia  Hypokalemia  COVID-19  Acute respiratory failure with hypoxia (HCC)   HOSPITAL COURSE: 94-year-old female with history of hypertension, chronic obstructive pulmonary disease and dementia presents to the hospital for cough and shortness of breath.  Resides at a long-term care facility for advanced dementia.  Was reportedly treated for pneumonia 2 weeks ago however did not tolerate oral steroids given with antibiotics.  Was found to be more lethargic at facility requiring oxygen as a result brought to the ER.  In the ER patient was hypoxic and continued on 2 L nasal cannula.  Routine labs did show a slightly elevated BNP.  Procalcitonin was normal.  Potassium was low, D-dimer elevated.  Patient did test positive for COVID-19.  CTA chest did not demonstrate PE however very small pleural effusions were noted.  Patient was hospitalized and treated with Decadron and remdesivir.  Patient was also treated with Lasix once potassium corrected.  Patient is breathing quickly returned back to baseline and patient is weaned off of oxygen.  Patient did react to the steroids as predicted and became more confused however was redirectable.  Patient will return back to prior facility and resume care there.  Will be discharged with remaining course of Decadron, Lasix and increase blood pressure medications
Day after vaccination had pin point, red dot, pimple like rash on ankles, toes, hands, between fingers and on arms with no blisters and no complaints of itching.
Pt presented to office on 2/10/12 with c/o left arm redness, edema, and warmth. States it started on 2/08. Pt was given 80mg DEPO-MEDROL in office after Dr evaluated.
pt began vomiting on 28FEB97 t/c to MD on call 2MAR97 711PM describes vomiting no diarrhea no blood in vomit;urinating, sleeping but easily arousable;advice given w/instructions to call back if sx inc & in AM for appointment;
5/15/21 sudden onset of Chest, throat, jaw and left arm pain; lightheadedness & nausea with heart pounding. EMS called, cardiac monitor showed ventricular tachycardia in 250s. I was taken to Hospital. I was Cardioverted twice (200j) in the Emergency department; Immediately following Cardioversion taken to Cath lab where no Coronary Artery Disease was noted. Amiodarone intravenous infusion started in ICU. After 4 days in ICU I was transferred for possible Myocarditis and for pacemaker/defibrillator placement. I was in the Cardiac ICU 5 days. After Cardioversion I continued to have runs of ventricular tachycardia so Amiodarone IV was started.
PT EXPER RASH(URTICARIAL, BRIGHT RED, SLIGHTLY RAISED, NO WHEALS)FROM HEAD TO TOE WITHIN 12 HRS AFTER IMMUNIZATION. WITHIN 24 HRS,EYES BECAME SWOLLEN;NO BREATHING DIFF. TREATED /W/ BENADRYL & TYLENOL ORALLY. DURATION OF RASH APPROX 48 HRS.
She complained of severe headache, fever of up to 101.7, dizziness, & sleepiness for 2 days. No treatment. She'd had the Flu-mist vaccine, the day before she got sick.
after 5hrs of getting the shot I lost movement in my left arm from the elbow  up the left side of my neck due to excruciating pain which lasted for 48 hours slowly got movement back the third day; after 5hrs of getting the shot I lost movement in my left arm from the elbow  up the left side of my neck due to excruciating pain which lasted for 48 hours slowly got movement back the third day; after 5hrs of getting the shot I lost movement in my left arm from the elbow  up the left side of my neck due to excruciating pain which lasted for 48 hours slowly got movement back the third day; This is a spontaneous report from a contactable consumer or other non hcp (Patient himself). A 72-year-old male patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Lot Number: EL9261), dose 1 via an unspecified route of administration, administered in Arm Left on 29Jan2021 at 10:45 (Age at vaccination: 72 Years) as DOSE 1, SINGLE for COVID-19 immunisation. Medical history included penicillin allergy from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient had no other medical history. The patient was not diagnosed with COVID-19 prior to vaccination and not since the vaccination. She did not receive any prior vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine and received any other medications the patient received within 2 weeks of vaccination. The patient experienced after 5hrs of getting the shot I lost movement in my left arm from the elbow up the left side of my neck due to excruciating pain which lasted for 48 hours slowly got movement back the third day on 29Jan2021 at 16:45. She took a treatment as (8 Tylenol 500). Therapeutic measures were taken as a result of the event. The outcome of the events was recovering.  Follow-up attempts are completed. No further information is expected.
SBO (small bowel obstruction). ED visit to hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
Sore arm x 36 hours.  1 doses of Acetaminophen; 1 dose of Ibuprofen.
Chills; Fever; Headache; This is a spontaneous report from a non-contactable healthcare professional, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 12Apr2021 at 09:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 19Mar2021 at 10:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 23:00, the patient experienced chills, fever and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever and headache was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected